Saihe Medical Completes Over RMB 200 Million Series B Financing to Accelerate Commercialization of Innovative Vascular Intervention Solutions

VCBeat learned第一时间获悉，近日，SONOSEMI, a provider of active interventional diagnosis and treatment solutions for泛血管 in China — Sonosemi Medical Co., Ltd. (hereinafter referred to as "SONOSEMI") — has completed a B-round financing of over 200 million RMB., this round of financing was led byGuangzhou YUEXIU Industrial Investment Fund Management Co.,Ltd.AndBeijing Jianxin Private Equity Fund L.P.Co-led by,Cornerstone CapitalFollow-on Investment, Original ShareholderShenzhen Tencent Industrial Fund Co., Ltd., FIL Capital Management (Hong Kong) Limited, Beijing Alwin Asset Management, Ltd.The continuous investment demonstrates the investors' confidence in the company's future development. Dianshi Capital serves as the exclusive financial advisor. The funds raised in this round will be used for the research, development, production, and commercialization of core products.

SONOSEMI Medical, founded in April 2020 and headquartered in Shenzhen, has broken through the technical barriers of high-end overseas medical devices over three years of development. The company has independently developed innovative active interventional products for pan-vascular applications, including a coronary intravascular shockwave treatment system, a peripheral arterial intravascular shockwave treatment system, an intracardiac ultrasound imaging system, and intravascular ultrasound. It is expected that by the end of 2024, SONOSEMI will form a product portfolio comprising 4-6 products, providing customers with comprehensive integrated solutions.

SONOSEMI Medical focuses on innovative product matrices for precise interventional diagnosis and treatment in coronary, peripheral, structural heart disease, and electrophysiology. Addressing unmet clinical needs and pain points in existing interventional therapies, the company simplifies surgical procedures, improves operational efficiency, reduces medical costs, and collaborates with industry partners and supply chain resources to provide patients with more environmentally friendly, safe, cost-effective, and efficient universal solutions.

As of now, SONOSEMI has applied for more than 100 patents of various kinds, including over 50 invention patents. It has maintained a leading technological edge in the field of active peripheral vascular intervention, achieved the domestic production of active peripheral vascular intervention products, and filled the gap in China's industry.

In the recently concluded 15th China Shenzhen Innovation and Entrepreneurship Competition 2023, SONOSEMI Medical stood out from thousands of participating companies over several months with its project "Coronary Artery Shock Wave Treatment System" and won the Excellent Award in the finals of the biopharmaceutical enterprise group.

The award-winning project this time is SONOSEMI's independently developed "Coronary Artery Shock Wave Treatment System," which utilizes an innovative vascular calcification plaque cracking technology. It achieves a technical integration of traditional electrohydraulic lithotripsy and balloon angioplasty, creatively applying it to the treatment of coronary artery calcification lesions. By pre-treating the vascular lumen and cracking existing calcified plaques, the system significantly improves vascular compliance.

The 6-month results of the system's registered clinical trial have been重磅 announced at this year's China Interventional Cardiology Conference (CIT2023). The trial results fully demonstrate its safety and effectiveness, providing a new treatment option for clinical practice. It is reported that SONOSEMI's coronary artery shock wave therapy system is accelerating its market launch, hoping to serve a large number of patients as soon as possible.

SONOSEMI's founder, Mr. Liu Bin, stated: "Thank you to the original shareholders and investors in this round for their support and recognition. This round of financing comes just before the commercialization of our product. SONOSEMI will continue to fulfill its innovative mission, accelerate the process of bringing products to market, and benefit more patients as soon as possible, bringing good news to patients with泛vascular diseases worldwide.。”

After the completion of this round of financing, SONOSEMI will continue to focus on the product layout and development of pan-vascular precision diagnosis and treatment solutions, enriching and continuously iterating the company’s product portfolio. Meanwhile, SONOSEMI has set its sights on the international market, actively laying out global patents, and advancing overseas registration and clinical plans.